Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Norvir

Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 15

HOS-086232 · Präparat HOS-083284

Anticoagulants Dabigatran etexilate Serum concentrations may be increased due to P-gp inhibition by ritonavir. Clinical Edoxaban monitoring and/or dose reduction of the direct oral anticoagulants (DOAC) should be considered when a DOAC transported by P-gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co-administered with ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): edoxaban (HOS-086234) dabigatran etexilate (HOS-086233)

Wechselwirkungen · Norvir

Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 47

HOS-086430 · Präparat HOS-083284

Anticoagulants Dabigatran etexilate Serum concentrations may be increased due to P-gp inhibition by ritonavir. Clinical Edoxaban monitoring and/or dose reduction of the direct oral anticoagulants (DOAC) should be considered when a DOAC transported by P-gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co-administered with ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): edoxaban (HOS-086234) dabigatran etexilate (HOS-086233)

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 15–16

HOS-108886 · Präparat HOS-093083

15 Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose Edoxaban Edoxaban: reduction of the direct oral Serum concentrations may be anticoagulants (DOAC) should be increased due to P-gp inhibition considered when a DOAC by lopinavir/ritonavir. transported by P-gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co-administered with Kaletra. Anticonvulsants Phenytoin Phenytoin: Caution should be exercised in Steady-state concentrations was administering phenytoin with moderately decreased due to Kaletra. CYP2C9 and CYP2C19 induction by lopinavir/ritonavir. Phenytoin levels should be monitored when co-administering Lopinavir: with Kaletra. Concentrations are decreased due to CYP3A induction by When co-administered with phenytoin. phenytoin, an increase of Kaletra dosage may be envisaged. Dose adjustment has not been evaluated in clinical practice. Carbamazepine and Carbamazepine: Caution should be exercised in Phenobarbital Serum concentrations may be administering carbamazepine or increased due to CYP3A phenobarbital with Kaletra. inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital Lopinavir: levels should be monitored when Concentrations may be decreased co-administering with Kaletra. due to CYP3A induction by carbamazepine and phenobarbital. When co-administered with carbamazepine or phenobarbital, an increase of Kaletra dosage may be envisaged. Dose adjustment has not been evaluated in clinical practice

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52

HOS-109010 · Präparat HOS-093083

For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions). Patients should be closely monitored for signs related to venetoclax toxicities. Anticoagulants Warfarin Warfarin: It is recommended that INR Concentrations may be affected (international normalised ratio) be when co-administered with monitored. lopinavir/ritonavir due to CYP2C9 induction. Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban and AUC: ↑ 153% Kaletra may increase rivaroxaban (Ritonavir 600 mg twice Cmax: ↑ 55% exposure which may increase the risk daily) Due to CYP3A and P-gp of bleeding. inhibition by lopinavir/ritonavir. The use of rivaroxaban is not recommended in patients receiving concomitant treatment with Kaletra (see section 4.4). Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose Edoxaban Edoxaban: reduction of the direct oral Serum concentrations may be anticoagulants (DOAC) should be increased due to Pgp inhibition by considered when a DOAC lopinavir/ritonavir. transported by P-gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co-administered with Kaletra. Anticonvulsants Phenytoin Phenytoin: Caution should be exercised in Steady-state concentrations was administering phenytoin with Kaletra. moderately decreased due to Phenytoin levels should be monitored CYP2C9 and CYP2C19 induction when co-administering with Kaletra. by lopinavir/ritonavir. When co-administered with phenytoin, an increase of Kaletra Lopinavir: dosage may be envisaged. Dose Concentrations are decreased due adjustment has not been evaluated in to CYP3A induction by clinical practice. phenytoin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): venetoclax (HOS-086143) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 87–88

HOS-109085 · Präparat HOS-093083

87 Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban AUC: ↑ 153% and Kaletra may increase (Ritonavir 600 mg twice Cmax: ↑ 55% rivaroxaban exposure which may daily) Due to CYP3A and P-gp increase the risk of bleeding. inhibition by lopinavir/ritonavir. The use of rivaroxaban is not recommended in patients receiving concomitant treatment with Kaletra (see section 4.4). Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose Edoxaban Edoxaban: reduction of the direct oral Serum concentrations may be anticoagulants (DOAC) should be increased due to Pgp inhibition by considered when a DOAC lopinavir/ritonavir. transported by P-gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co-administered with Kaletra. Anticonvulsants Phenytoin Phenytoin: Caution should be exercised in Steady-state concentrations was administering phenytoin with moderately decreased due to Kaletra. CYP2C9 and CYP2C19 induction Phenytoin levels should be by lopinavir/ritonavir. monitored when co-administering with Kaletra. Lopinavir: When co-administered with Concentrations are decreased due phenytoin, an increase of Kaletra to CYP3A induction by dosage may be envisaged. Dose phenytoin. adjustment has not been evaluated in clinical practice. Kaletra must not be administered once daily in combination with phenytoin. Carbamazepine and Carbamazepine: Caution should be exercised in Phenobarbital Serum concentrations may be administering carbamazepine or increased due to CYP3A phenobarbital with Kaletra. inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital levels should be monitored when Lopinavir: co-administering with Kaletra. Concentrations may be decreased When co-administered with due to CYP3A induction by carbamazepine or phenobarbital, an carbamazepine and phenobarbital. increase of Kaletra dosage may be envisaged. Dose adjustment has not been evaluated in clinical practice. Kaletra must not be administered once daily in combination with carbamazepine and phenobarbital. Lamotrigine and Lamotrigine: Patients should be monitored Valproate AUC: ↓ 50% closely for a decreased VPA effect Cmax: ↓ 46% when Kaletra and valproic acid or Cmin: ↓ 56% valproate are given concomitantly.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 18

HOS-112098 · Präparat HOS-093615

Potential P-gp inhibition by REYATAZ is unknown and cannot be excluded. Edoxaban Potential for increased edoxaban Exercise caution when edoxaban is concentrations which can result in a higher used with REYATAZ. risk of bleeding. The mechanism of interaction is P-gp inhibition by Please refer to the edoxaban SmPC REYATAZ/ritonavir. sections 4.2 and 4.5 for appropriate edoxaban dosage recommendations Ritonavir is a strong P-gp inhibitor. for co-administration with P-gp inhibitors. Potential P-gp inhibition by REYATAZ is unknown and cannot be excluded. Vitamin K antagonists Warfarin Co-administration with REYATAZ has the It is recommended that the potential to increase or decrease warfarin International Normalised Ratio concentrations. (INR) be monitored carefully during treatment with REYATAZ, especially when commencing therapy. ANTIEPILEPTICS Carbamazepine REYATAZ may increase plasma levels of Carbamazepine in combination carbamazepine due to CYP3A4 inhibition. with REYATAZ (with or without ritonavir) is contraindicated due to Due to carbamazepine inducing effect, a the risk for loss of virologic reduction in REYATAZ exposure cannot response and development of be ruled out. resistance (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) vitamin K (HOS-091176) edoxaban (HOS-086234) ritonavir (HOS-084521) warfarin (HOS-085950)

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 53

HOS-112188 · Präparat HOS-093615

Potential P-gp inhibition by REYATAZ is unknown and cannot be excluded. Edoxaban Potential for increased edoxaban Exercise caution when concentrations which can result in a higher edoxaban is used with risk of bleeding. The mechanism of REYATAZ. interaction is P-gp inhibition by REYATAZ/ritonavir. Please refer to the edoxaban SmPC sections 4.2 and 4.5 for Ritonavir is a strong P-gp inhibitor. appropriate edoxaban dosage recommendations for Potential P-gp inhibition by REYATAZ is co-administration with P-gp unknown and cannot be excluded. inhibitors. Vitamin K antagonists Warfarin Co-administration with REYATAZ has the It is recommended that the potential to increase or decrease warfarin International Normalised Ratio concentrations. (INR) be monitored carefully during treatment with REYATAZ, especially when commencing therapy. ANTIEPILEPTICS Carbamazepine REYATAZ may increase plasma levels of Carbamazepine in combination carbamazepine due to CYP3A4 inhibition. with REYATAZ (with or without ritonavir) is Due to carbamazepine inducing effect, a contraindicated due to the risk reduction in REYATAZ exposure cannot for loss of virologic response be ruled out. and development of resistance (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) vitamin K (HOS-091176) edoxaban (HOS-086234) ritonavir (HOS-084521) warfarin (HOS-085950)

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 15–16

HOS-116363 · Präparat HOS-094447

15 ANTIBIOTIC Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when 500 mg twice daily clarithromycin Cmin ↑ 174% clarithromycin is combined with clarithromycin Cmax ↑ 26% boosted PREZISTA. # darunavir AUC ↓ 13% # darunavir Cmin ↑ 1% For patients with renal impairment # the Summary of Product darunavir Cmax ↓ 17% Characteristics for clarithromycin 14-OH-clarithromycin concentrations should be consulted for the were not detectable when combined with recommended dose. PREZISTA/ritonavir. (↑ clarithromycin from CYP3A inhibition and possible P-gp inhibition) ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR Apixaban Not studied. Co-administration of The use of boosted PREZISTA Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant anticoagulants may increase (DOAC) that is metabolised by concentrations of the anticoagulant. CYP3A4 and transported by P-gp (CYP3A and/or P-gp inhibition) is not recommended as this may lead to an increased bleeding risk. Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir: Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose dose: reduction of the DOAC should be dabigatran AUC ↑ 72% considered when a DOAC dabigatran Cmax ↑ 64% transported by P-gp but not metabolised by CYP3A4, darunavir/ritonavir 800/100 mg once including dabigatran etexilate and daily: edoxaban, is co-administered with dabigatran AUC ↑ 18% PREZISTA/rtv. dabigatran Cmax ↑ 22% Darunavir/cobicistat: darunavir/cobicistat 800/150 mg single Clinical monitoring and dose dose: reduction is required when a dabigatran AUC ↑ 164% DOAC transported by P-gp but not dabigatran Cmax ↑ 164% metabolised by CYP3A4, including dabigatran etexilate and darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with daily: PREZISTA/cobi. dabigatran AUC ↑ 88% dabigatran Cmax ↑ 99% Ticagrelor Concomitant administration of Based on theoretical considerations, boosted PREZISTA with ticagrelor co-administration of boosted PREZISTA is contraindicated (see section 4.3). with ticagrelor may increase concentrations of ticagrelor (CYP3A and/or P-glycoprotein inhibition). Clopidogrel Co-administration of clopidogrel Not studied. Co-administration of with boosted PREZISTA is not clopidogrel with boosted PREZISTA is recommended. Use of other expected to decrease clopidogrel active antiplatelets not affected by CYP metabolite plasma concentration, which inhibition or induction (e.g. may reduce the antiplatelet activity of prasugrel) is recommended. clopidogrel. Warfarin Not studied. Warfarin concentrations may It is recommended that the be affected when co-administered with international normalised ratio boosted PREZISTA. (INR) be monitored when warfarin is combined with boosted PREZISTA.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) cobicistat (HOS-088111) dabigatran (HOS-112096) rivaroxaban (HOS-086236) lead (HOS-085592) clopidogrel (HOS-087927) clarithromycin (HOS-084517) edoxaban (HOS-086234) apixaban (HOS-112091) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) warfarin (HOS-085950)

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 57–58

HOS-116518 · Präparat HOS-094447

57  Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir: Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose dose: reduction of the DOAC should be dabigatran AUC ↑ 72% considered when a DOAC dabigatran Cmax ↑ 64% transported by P-gp but not metabolised by CYP3A4, darunavir/ritonavir 800/100 mg once including dabigatran etexilate and daily: edoxaban, is co-administered with dabigatran AUC ↑ 18% PREZISTA/rtv. dabigatran Cmax ↑ 22%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran (HOS-112096) edoxaban (HOS-086234) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233)

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 97–98

HOS-116609 · Präparat HOS-094447

97  Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir: Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose dose: reduction of the DOAC should be dabigatran AUC ↑ 72% considered when a DOAC dabigatran Cmax ↑ 64% transported by P-gp but not metabolised by CYP3A4, darunavir/ritonavir 800/100 mg once including dabigatran etexilate and daily: edoxaban, is co-administered with dabigatran AUC ↑ 18% PREZISTA/rtv. dabigatran Cmax ↑ 22% Darunavir/cobicistat: darunavir/cobicistat 800/150 mg single Clinical monitoring and dose dose: reduction is required when a dabigatran AUC ↑ 164% DOAC transported by P-gp but not dabigatran Cmax ↑ 164% metabolised by CYP3A4, including dabigatran etexilate and darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with daily: PREZISTA/cobi. dabigatran AUC ↑ 88% dabigatran Cmax ↑ 99% Ticagrelor Based on theoretical considerations, Concomitant administration of co-administration of boosted PREZISTA boosted PREZISTA with ticagrelor with ticagrelor may increase is contraindicated (see section 4.3). concentrations of ticagrelor (CYP3A and/or P-glycoprotein inhibition). Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel clopidogrel with boosted PREZISTA is with boosted PREZISTA is not expected to decrease clopidogrel active recommended. Use of other metabolite plasma concentration, which antiplatelets not affected by CYP may reduce the antiplatelet activity of inhibition or induction (e.g. clopidogrel prasugrel) is recommended. Warfarin Not studied. Warfarin concentrations may It is recommended that the be affected when co-administered with international normalised ratio boosted PREZISTA. (INR) be monitored when warfarin is combined with boosted PREZISTA. ANTICONVULSANTS Phenobarbital Not studied. Phenobarbital and phenytoin PREZISTA co-administered with Phenytoin are expected to decrease plasma low dose ritonavir should not be concentrations of darunavir and its used in combination with these pharmacoenhancer. medicines. (induction of CYP450 enzymes) The use of these medicines with PREZISTA/cobicistat is contraindicated (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) phenobarbital (HOS-085617) cobicistat (HOS-088111) dabigatran (HOS-112096) clopidogrel (HOS-087927) edoxaban (HOS-086234) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)

Gegenanzeigen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 7

HOS-127786 · Präparat HOS-096471

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 7

HOS-127787 · Präparat HOS-096471

Clinically significant active bleeding.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 7

HOS-127788 · Präparat HOS-096471

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 7

HOS-127789 · Präparat HOS-096471

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 7–8

HOS-127790 · Präparat HOS-096471

7 brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 8

HOS-127791 · Präparat HOS-096471

Uncontrolled severe hypertension.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 8

HOS-127792 · Präparat HOS-096471

Concomitant treatment with any other anticoagulants e.g. UFH, LMWH (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, rivaroxaban, apixaban etc.) except under specific circumstances of switching oral anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fondaparinux (HOS-110096) heparin (HOS-086930) rivaroxaban (HOS-086236) apixaban (HOS-112091) enoxaparin (HOS-118623) dabigatran etexilate (HOS-086233) dalteparin (HOS-118624) warfarin (HOS-085950)

Gegenanzeigen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 8

HOS-127800 · Präparat HOS-096471

Pregnancy and breast-feeding (see section 4.6).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-127801 · Präparat HOS-096471

Edoxaban is predominantly absorbed in the upper gastrointestinal (GI) tract. Thus, medicinal products or disease conditions that increase gastric emptying and gut motility have the possibility of reducing edoxaban dissolution and absorption.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lixiana

Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-127802 · Präparat HOS-096471

P-gp inhibitors

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.